1	Exploring the impact of an artificial intelligence-based intraoperative image
2	navigation system in laparoscopic surgery on clinical outcomes: A protocol for a
3	multicenter randomized controlled trial
4	
5	Daichi Kitaguchi <sup>1,2,3</sup> , Nozomu Fuse <sup>4</sup> , Masashi Wakabayashi <sup>5</sup> , Norihito Kosugi <sup>1,2</sup> , Yuto
6	Ishikawa <sup>1,2</sup> , Kazuyuki Hayashi <sup>1,2</sup> , Hiro Hasegawa <sup>2,3</sup> , Nobuyoshi Takeshita <sup>2</sup> , Masaaki
7	Ito <sup>2,3*</sup>
8	
9	<sup>1</sup> AI Digital Device Innovation Office, National Cancer Center Hospital East, Chiba, Japan
10	<sup>2</sup> Department for the Promotion of Medical Device Innovation, National Cancer Center Hospital
11	East, Chiba, Japan
12	<sup>3</sup> Department of Colorectal Surgery, National Cancer Center Hospital East, Chiba, Japan
13	<sup>4</sup> Clinical Research Support Office, National Cancer Center Hospital East, Chiba, Japan
14	<sup>5</sup> Biostatistics Division, Center for Research Administration and Support, National Cancer
15	Center Hospital East, Chiba, Japan
16	
17	*Corresponding author:
18	Masaaki Ito, MD, PhD
19	Department for the Promotion of Medical Device Innovation
20	Department of Colorectal Surgery
21	National Cancer Center Hospital East
22	6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
23	E-mail: maito@east.ncc.go.jp, Tel: +81-4-7133-1111, Fax: +81-4-7130-0199
24	

#### 25 Abstract

**Background:** In the research field of artificial intelligence (AI) in surgery, there are many open questions that must be clarified. Well-designed randomized controlled trials (RCTs) are required to explore the positive clinical impacts by comparing the use and non-use of AI-based intraoperative image navigation. Therefore, herein, we propose the "ImNavi" trial, a multicenter RCT, to compare the use and non-use of an AI-based intraoperative image navigation system in laparoscopic surgery.

Methods: The ImNavi trial is a Japanese multicenter RCT involving 1:1 randomization 32 between the use and non-use of an AI-based intraoperative image navigation system in 33 laparoscopic colorectal surgery. The participating institutions will include three 34 35 high-volume centers with sufficient laparoscopic colorectal surgery caseloads (>100 36 cases/year), including one national cancer center and two university hospitals in Japan. 37 Written informed consent will be obtained from all patients. Patients aged between 18 38 and 80 years scheduled to undergo laparoscopic left-sided colorectal resection will be 39 included in the study. The primary outcome is the time required for each target organ, 40 including the ureter and autonomic nerves, to be recognized by the surgeon after its initial appearance on the monitor. Secondary outcomes include intraoperative target 41 42 organ injuries, intraoperative complications, operation time, blood loss, duration of postoperative hospital stay, postoperative complications within 30 days, postoperative 43 male sexual dysfunction 1 month after surgery, surgeon's confidence in recognizing 44 45 each target organ, and the postoperative fatigue of the primary surgeon.

46 **Discussion:** The impact of AI-based surgical applications on clinical outcomes beyond 47 numerical expression will be explored from a variety of viewpoints while evaluating 48 quantitative items, including intraoperative complications and operation time, as

49 secondary endpoints. We expect that the findings of this RCT will contribute to
50 advancing research in the domain of AI in surgery.
51 Trial registration: The trial was registered at the University Hospital Medical

- 52 Information Network Center (<u>https://www.umin.ac.jp/ctr/index-j.html</u>) on March 28th,
- 53 2023 under trial ID: UMIN000050701.

54

#### 55 Keywords

Artificial intelligence, computer vision, semantic segmentation, intraoperative image
 navigation, computer-assisted surgery

58

### 59 Background

Surgical volumes are large and show an increasing trend worldwide [1]; 60 nevertheless, it is estimated that 143 million additional surgical procedures are required 61 annually to save lives and prevent disabilities [2]. Surgery is an essential aspect of 62 healthcare and is associated with increased life expectancy [1]; however, 63 64 inter-institutional disparities in surgical skill levels remain. The introduction of minimally invasive surgery (MIS), including endoscopic surgical approaches, has made 65 66 surgery more effective [3]. However, surgery has become more complex, and achieving 67 basic surgical skill levels, which are directly linked to postoperative clinical outcomes, 68 has become more difficult [4, 5]. Improvements in the safety and efficiency of surgery 69 must be a major component in strengthening healthcare systems, and technological innovation may be one of the solutions to achieve this goal. 70

Computer vision (CV) based on artificial intelligence (AI), particularly deep
 learning using convolutional neural networks, is a recent technological innovation.

73 AI-based CV is a field of computer science that enables AI to extract meaningful 74 information from digital images and videos, and to process and make recommendations based on that information [6]. In recent years, AI-based CV has achieved remarkable 75 76 success in image recognition tasks in the field of medical image diagnosis, such as 77 radiology [7-9], pathology [10, 11], gastroenterology [12], and ophthalmology [13-15]. 78 In the field of surgery, several AI-based CV applications for MIS, specifically semantic 79 segmentation-based intraoperative image navigation, have been developed based on the nature of MIS, which relies heavily on the visual information provided by surgical 80 endoscopes [16-18]. These are expected to reduce intraoperative anatomical cognitive 81 errors. However, the majority of studies in this field are still in the proof-of-concept 82 83 stage.

84 In the research field of AI in surgery, many open questions regarding how AI-based intraoperative image navigation affects surgeon performance exist, including whether it 85 86 can achieve some improvement in clinical outcomes, and whether it works properly in 87 diverse environments without overfitting. To address these questions, well-designed 88 randomized controlled trials (RCTs) are required to explore the positive clinical impacts of AI-based intraoperative image navigation. Therefore, we propose the "ImNavi" trial, 89 90 a multicenter RCT, to compare the use and non-use of an AI-based intraoperative image 91 navigation system in laparoscopic surgery.

92

#### 93 Methods/Design

#### 94 Participants, interventions, and outcomes

95 Trial design

96 The ImNavi trial is designed as a Japanese multicenter RCT with 1:1 randomization

97 between the use and non-use of an AI-based intraoperative image-navigation system in laparoscopic surgery. The study protocol was prepared according to the reporting 98 guidelines of the Standard Protocol Items: Recommendations for Interventional Trials -99 100 Artificial Intelligence extension (SPIRIT-AI) [19]. The SPIRIT-AI checklist is presented 101 in Additional File 1.

102

#### Study setting and recruitment 103

104 This hospital-based study will be conducted in Japan. Eligible candidates will be 105 identified from patients referred to a colorectal surgeon or colorectal cancer 106 multidisciplinary team based on colonoscopy, computed tomography, or magnetic 107 resonance imaging findings, and eligibility will be confirmed after a review of the study 108 criteria. The target surgical procedures in this study are left-sided colorectal resections, 109 including left hemicolectomy, sigmoidectomy, anterior resection, intersphincteric 110 resection, Hartmann's procedure, and abdominoperineal resection. The target organs for semantic segmentation are the ureter and autonomic nerves, including the hypogastric 111 112 nerves and the aortic plexus. The AI-based intraoperative image navigation system used in this study is based on an existing semantic segmentation algorithm that we developed 113 114 [20, 21]. The accuracy and performance of both the ureter recognition model (UreterNet) and the autonomic nerve recognition model (NerveNet) have been validated 115in our previous study [20]. Alienware x15 R2 (Dell Technologies Inc., Round Rock, 116 117 Texas, U.S.) was used as the computational system in this study.

118

#### 119 Eligibility criteria

120 Patients aged between 18 and 80 years scheduled to undergo laparoscopic left-sided

121 colorectal resection and who provided written informed consent will be included in the 122 ImNavi trial. Long-term outcomes will not be included in the endpoints; therefore, 123 patients with any colorectal disease will be eligible. Patients with emergent surgery, 124 expected severe intra-abdominal adhesion, significant anatomical anomaly, and those 125 deemed unsuitable by the doctor in charge will be excluded. The trial flow diagram is 126 illustrated in Figure 1.

127

### 128 Interventions

The time required to recognize each target organ, including the ureter and 129 autonomic nerves, after its initial appearance on the monitor will be compared between 130 131 the surgeons with and without an AI-based intraoperative image navigation system. The 132 initial time of appearance of each target organ will be retrospectively determined by two 133 or more judges observing via video. The system output, semantic segmentation pixels, will be superimposed on a sub-monitor placed adjacent to the main monitor, as 134 illustrated in Figure 2, without influencing the display of the main monitor. The 135 136 surgeons will decide the time and frequency of viewing the sub-monitor. The primary surgeon will be asked to orally state that they recognize each target organ during surgery. 137 138 All intraoperative statements made by the primary surgeon will be recorded by a microphone placed near the operating table. The intraoperative audio will be collated 139 140 with the intraoperative video, and the difference in time points between the initial appearance on the monitor and the primary surgeon's recognition (vocalization) will be 141 142 calculated for each target organ.

143

144 *Outcomes* 

The primary outcome is the time required for each target organ, including the ureter 145and autonomic nerves, to be recognized by the surgeon after its initial appearance on the 146 monitor. Secondary outcomes include intraoperative target organ injuries; intraoperative 147 complications; total operation time; operation time for each surgical step divided by 148 149 existing definitions [22]; blood loss; duration of postoperative hospital stay; 150 postoperative complications within 30 days; postoperative male sexual dysfunction 1 month post-surgery; the surgeon's confidence in recognising each target organ; and 151postoperative fatigue of the primary surgeon, according to the Piper Fatigue Scale-12 152(PFS-12) [23]. The severity of all intraoperative and postoperative complications, 153according to the Common Terminology Criteria for Adverse Events and the 154155 Clavien–Dindo classification, will also be collected as secondary outcomes.

156

### 157 Participant timelines

158 Before surgery, written informed consent will be obtained from all patients and their primary surgeons, and patients will be allocated to their respective groups using an 159160 electronic data capture (EDC) system. A preoperative report, including patient, disease, and primary surgeon background information, will be provided using case report forms 161 162 (CRFs). After surgery, an intraoperative report on the primary surgeon's surgical information and postoperative fatigue, according to the PFS-12, will be provided using 163 CRFs and questionnaires, respectively. One month after surgery, the postoperative 164 course and outcome reports, including postoperative complications and date of 165 166 discharge, will be provided using the CRFs. This study will not regulate modalities or 167 intervals between examinations for each participating institution, or intervene in each 168 institution's routine clinical practice.

169

### 170 Sample size

Based on non-published data from previous studies at our institution, the mean time 171 (± standard deviation) required by surgeons to recognize each target organ without using 172173the AI-based intraoperative image navigation system after its initial appearance on the 174monitor is estimated to be 6.0 ( $\pm$  9.0) s. To detect a 2-s decrease with the AI-based system, using a power of 80% and a one-sided significance level of 0.15 in the 175 Wilcoxon rank-sum test, 38 patients in each group (76 patients in total) would be 176 required for this RCT. After accounting for dropouts and ineligibility, an additional 14 177 patients will be included. Thus, the target sample size would be 90 patients. 178

179

### 180 Assignment of interventions

Once eligibility is established, patients will be allocated to either the use or non-use 181 of AI-based intraoperative image navigation groups. Randomization, performed by 182 computers through the Internet (https://www2.epoc-ncc.net/), will be adjusted using the 183 184 minimization method with a random component to balance the groups, participating institution, sex (male versus female), and experience of the primary surgeon (qualified 185 186 versus unqualified by the Endoscopic Surgical Skill Qualification System of the Japan Society for Endoscopic Surgery) [24]. Patients will be randomized in a 1:1 ratio. Data 187 188 will be analyzed on an 'intention-to-treat' basis when patients are not subjected to a randomized treatment modality. 189

190

## 191 Data collection, management, and analysis

192 Data collection will be carried out using CRFs and a validated PFS-12

questionnaire. All data will be entered into an EDC system. Regular data quality checks
will be performed annually in accordance with the Quality Management Plan. All data
will be handled following the Ethical Guidelines for Medical and Biological Research
Involving Human Subjects. Data backups will be stored in secure fireproof locations,
and test restorations will be performed regularly. After completion of the trial, all
essential trial documentation and source documents, including signed informed consent
forms and copies of CRFs, will be securely retained for at least 5 years.

200

#### 201 Statistical analysis

Baseline numerical data will be described as the mean ( $\pm$  standard deviation) or median (range). Baseline categorical data will be presented as percentages. All comparative analyses will be conducted on an 'intention-to-treat' basis. In addition to the intention-to-treat analysis, per-protocol and as-treated analyses will be applied as sensitivity analyses. Primary outcomes will be compared using the Wilcoxon's rank sum test. Secondary outcomes will be compared using the Fisher's exact test or the Wilcoxon's rank sum test, as necessary.

209

#### 210 Monitoring

Regular data quality checks will be performed yearly, per the Quality Management Plan. Central monitoring will be conducted by the data center based on the CRF data collected via the EDC system. The monitoring staff will prepare a monitoring report after central monitoring and report it to the principal investigator.

215

#### 216 Ethics and dissemination

217 The participating institutions will include three high-volume centers with sufficient laparoscopic colorectal surgery caseloads (>100 cases/year), including one national 218 cancer center and two university hospitals in Japan. The protocol for this RCT has been 219 reviewed and approved by the ethics committees of each participating institution, and 220 221 the trial has been registered at University Hospital Medical Information Network Center 222(https://www.umin.ac.jp/ctr/index-j.html) under the trial ID UMIN000050701. Written informed consent will be obtained from all patients after a thorough oral explanation by 223 224 the doctor in charge at each center participating in the ImNavi trial. All procedures will 225be conducted in accordance with the ethical standards of the Declaration of Helsinki.

226

#### 227 Discussion

228 Recently, analogous digital solutions have been translated and clinically implemented for diagnostic applications in gastrointestinal endoscopy [25] and 229 radiology [26]. In the field of surgery, several deep learning-based CV solutions have 230 been developed by academic and industry groups, mostly for MIS. Significant work has 231 232 also been performed on potential use cases [3]; however, no CV tools are widely used for diagnostic or therapeutic applications in surgery. Recently, an intraoperative AI 233234 system identifying anatomical landmarks for laparoscopic cholecystectomy has been developed and reported [18]; similarly, in the urological field, an AI alert system that 235236can predict the occurrence of intraoperative bleeding events during robotic surgery has been developed [27]. Although both systems could potentially be used as tools to 237 238 improve the safety of the intervention, they were only tested in a trial involving 10 239patients at a single center. Establishing solid evidence through RCTs is essential before 240 AI can be applied in surgery to move beyond the proof-of-concept step to clinical

implementation. In addition, a multicenter study design is desirable to eliminate bias
due to overfitting and to demonstrate generalization performance. This study is the first
multicenter RCT to be designed to explore the clinical significance of AI-based
intraoperative image navigation.

The target CV task of this study is the semantic segmentation of the ureter and 245 246 autonomic nerves in laparoscopic colorectal surgery. Iatrogenic ureteral injury in 247 colorectal surgery is a rare but potentially devastating complication of colorectal surgery. The incidence is approximately 0.5% - 1.5% [28-30]; however, a significant increase has 248 249 been observed with laparoscopy compared to open colectomies [29, 30] due to the lack of tactile information. In addition, trauma to the aortic plexus may occur during high 250 251ligation of the inferior mesenteric artery, and the superior hypogastric nerves may be injured along the sacral promontory or presacral region [31]. Injuries to the sympathetic 252nerves at this location affect the ability to ejaculate, including retrograde ejaculation, 253254whereas injuries to the parasympathetic nerves result in erectile dysfunction [31]. A previous study reported a decrease in male sexual function following colorectal surgery, 255256 with a decrease from 78 to 32% in ejaculatory function, 71 to 24% in erectile function, 257and 82 to 57% in sexual activity [32]; these dysfunctions are often overlooked but 258should be strictly avoided.

The time required for recognition of each target organ by surgeons after its initial appearance on the monitor was set as the primary endpoint of this study, with the expectation that the AI-based intraoperative image navigation system would contribute to the more rapid recognition of target organs. Intraoperative target organ injury is a more straightforward primary endpoint; however, the number of events was considered too small for analysis. In addition, we believe that more rapid recognition of key

265 anatomical landmarks during surgery can lead to several benefits other than prevention 266 of organ injury, such as identification of the correct dissection plane, and confidence in 267 proceeding with the procedure. The impact of AI-based surgical applications on clinical 268 outcomes beyond numerical expression will be explored from various facets while 269 evaluating quantitative items, including intraoperative complications and operation time, 270 as secondary endpoints. Furthermore, we expect that the findings of this RCT will 271 contribute to advancing research in the domain of AI in surgery.

272

## Strengths and limitations of this study

- The ImNavi trial is a Japanese multicenter RCT with 1:1 randomization between the use and non-use of an artificial intelligence-based intraoperative image-navigation system in laparoscopic surgery.
- Eligible candidates will be identified from patients referred to a colorectal
   surgeon or colorectal cancer multidisciplinary team based on colonoscopy,
   computed tomography, or magnetic resonance imaging findings, and eligibility
   will be confirmed following a review of the criteria.
- The primary outcome is the time required for each target organ to be recognized by the surgeon after its initial appearance on the monitor.
- Secondary outcomes include intraoperative target organ injuries; intraoperative complications; total operation time; operation time for each surgical step divided by existing definitions; blood loss; duration of postoperative hospital stay; postoperative complications within 30 days; postoperative male sexual dysfunction 1 month after surgery; surgeon's confidence in recognition of each target organ; and postoperative fatigue of the primary surgeon, according to the Piper Fatigue Scale-12.

289	•	The severity of all intraoperative and postoperative complications, measured
290		according to Common Terminology Criteria for Adverse Events and the
291		Clavien–Dindo classification, will also be collected as secondary outcomes.

#### 292 Trial Status

- This trial represents the first version of the study protocol. This trial was registered at 293 294the University Hospital Medical Information Network Center 2023 295(https://www.umin.ac.jp/ctr/index-j.html) on March 28th, (trial ID: 296 UMIN000050701). Recruitment will begin on June 2023 and is scheduled to be
- completed by December 2024.
- 298

#### 299 LIST OF ABBREVIATIONS

- 300 *AI*: artificial intelligence
- 301 *RCT*: randomized controlled trials
- 302 *MIS*: minimally invasive surgery
- 303 *CV*: computer vision
- 304 *EDC*: electronic data capture
- 305 *CRF*: case report forms
- 306

### 307 **DECLARATIONS**

#### 308 Ethics approval and consent to participate

309 The protocol for this RCT has been reviewed and approved by the ethics committees of

- and the trial has been registered at the University Hospital
- 311 Medical Information Network Center (https://www.umin.ac.jp/ctr/index-j.html) under
- the trial ID UMIN000050701. Written informed consent will be obtained from all

- 313 patients after a thorough oral explanation by the doctor in charge at each center
- 314 participating in the ImNavi trial. All procedures will be conducted in accordance with
- the ethical standards of the Declaration of Helsinki.
- 316 **Consent for publication**
- 317 Not applicable
- 318 Availability of data and materials
- 319 Not applicable
- 320 Competing interests
- 321 The authors declare that they have no competing interests.

## 322 Funding

- 323 This research is supported by the National Cancer Center Japan Research and
- 324 Development Fund, grant number 2022-A-11.

## 325 Authors' contributions

- 326 All authors made substantial contributions to the study concept or data analysis and
- 327 interpretation; drafted the manuscript or revised it critically for important intellectual
- 328 content; approved the final version of the manuscript to be published; and agreed to be
- 329 accountable for all aspects of the work.

## 330 Acknowledgements

- 331 We would like to thank all the members of the Clinical Research Support Office of the
- 332 National Cancer Center Hospital East for their continuous support during the planning
- 333 of this study.
- 334

335

## 336 **References**

- Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, et
   al. Estimate of the global volume of surgery in 2012: an assessment supporting
   improved health outcomes. Lancet. 2015;385 Suppl 2:S11.
- Meara JG, Leather AJ, Hagander L, Alkire BC, Alonso N, Ameh EA, et al.
   Global Surgery 2030: evidence and solutions for achieving health, welfare, and
   economic development. Lancet. 2015;386:569-624.
- 343 3. Mascagni P, Alapatt D, Sestini L, Altieri MS, Madani A, Watanabe Y, et al.
  344 Computer vision in surgery: from potential to clinical value. NPJ Digit Med.
  345 2022;5:163.
- Birkmeyer JD, Finks JF, O'Reilly A, Oerline M, Carlin AM, Nunn AR, et al.
   Surgical skill and complication rates after bariatric surgery. N Engl J Med.
   2013;369:1434-42.
- 5. Curtis NJ, Foster JD, Miskovic D, Brown CSB, Hewett PJ, Abbott S, et al.
  Association of surgical skill assessment with clinical outcomes in cancer surgery.
  JAMA Surg. 2020;155:590-8.
- Kitaguchi D, Takeshita N, Hasegawa H, Ito M. Artificial intelligence-based
  computer vision in surgery: Recent advances and future perspectives. Ann
  Gastroenterol Surg. 2022;6:29-36.
- McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et
  al. International evaluation of an AI system for breast cancer screening. Nature.
  2020;577:89-94.
- Ardila D, Kiraly AP, Bharadwaj S, Choi B, Reicher JJ, Peng L, et al. End-to-end
   lung cancer screening with three-dimensional deep learning on low-dose chest

360 computed tomography. Nat Med. 2019;25:954-61.

- 9. Huang P, Lin CT, Li Y, Tammemagi MC, Brock MV, Atkar-Khattra S, et al.
  Prediction of lung cancer risk at follow-up screening with low-dose CT: a
  training and validation study of a deep learning method. Lancet Digit Health.
  2019;1:e353-62.
- Kather JN, Pearson AT, Halama N, Jäger D, Krause J, Loosen SH, et al. Deep
  learning can predict microsatellite instability directly from histology in
  gastrointestinal cancer. Nat Med. 2019;25:1054-6.
- Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial
  intelligence in digital pathology new tools for diagnosis and precision oncology.
  Nat Rev Clin Oncol. 2019;16:703-15.
- Zhou D, Tian F, Tian X, Sun L, Huang X, Zhao F, et al. Diagnostic evaluation of
  a deep learning model for optical diagnosis of colorectal cancer. Nat Commun.
  2020;11:2961.
- Liu H, Li L, Wormstone IM, Qiao C, Zhang C, Liu P, et al. Development and
  validation of a deep learning system to detect glaucomatous optic neuropathy
  using fundus photographs. JAMA Ophthalmol. 2019;137:1353-60.
- Milea D, Najjar RP, Zhubo J, Ting D, Vasseneix C, Xu X, et al. Artificial
  intelligence to detect papilledema from ocular fundus photographs. N Engl J
  Med. 2020;382:1687-95.
- Xie Y, Nguyen QD, Hamzah H, Lim G, Bellemo V, Gunasekeran DV, et al.
  Artificial intelligence for teleophthalmology-based diabetic retinopathy
  screening in a national programme: an economic analysis modelling study.
  Lancet Digit Health. 2020;2:e240-9.

384	16.	Madani A, Namazi B, Altieri MS, Hashimoto DA, Rivera AM, Pucher PH, et al.
385		Artificial intelligence for intraoperative guidance: using semantic segmentation
386		to identify surgical anatomy during laparoscopic cholecystectomy. Ann Surg.
387		2022:276:363-9.

- Mascagni P, Vardazaryan A, Alapatt D, Urade T, Emre T, Fiorillo C, et al.
  Artificial intelligence for surgical safety: automatic assessment of the critical
  view of safety in laparoscopic cholecystectomy using deep learning. Ann Surg.
  2022;275:955-61.
- Nakanuma H, Endo Y, Fujinaga A, Kawamura M, Kawasaki T, Masuda T, et al.
  An intraoperative artificial intelligence system identifying anatomical landmarks
  for laparoscopic cholecystectomy: a prospective clinical feasibility trial
  (J-SUMMIT-C-01). Surg Endosc. 2023;37:1933-42.
- Cruz Rivera S, Liu X, Chan AW, Denniston AK, Calvert MJ. Guidelines for
  clinical trial protocols for interventions involving artificial intelligence: the
  SPIRIT-AI extension. Lancet Digit Health. 2020;2:e549-60.
- Kitaguchi D, Harai Y, Kosugi N, Hayashi K, Kojima S, Ishikawa Y, et al.
  Artificial intelligence for the recognition of key anatomical structures in
  laparoscopic colorectal surgery. Br J Surg. 2023;110:1355-8.
- 402 21. Kojima S, Kitaguchi D, Igaki T, Nakajima K, Ishikawa Y, Harai Y, et al.
  403 Deep-learning-based semantic segmentation of autonomic nerves from
  404 laparoscopic images of colorectal surgery: an experimental pilot study. Int J Surg.
  405 2023;109:813-20.
- 406 22. Kitaguchi D, Takeshita N, Matsuzaki H, Oda T, Watanabe M, Mori K, et al.
  407 Automated laparoscopic colorectal surgery workflow recognition using artificial

408	intelligence: Experimental research. Int J Surg. 2020;79:88-94.

- Reeve BB, Stover AM, Alfano CM, Smith AW, Ballard-Barbash R, Bernstein L,
  et al. The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item
  reduction in a cohort of breast cancer survivors. Breast Cancer Res Treat.
  2012;136:9-20.
- 413 24. Mori T, Kimura T, Kitajima M. Skill accreditation system for laparoscopic
  414 gastroenterologic surgeons in Japan. Minim Invasive Ther Allied Technol.
  415 2010;19:18-23.
- 416 25. Hassan C, Spadaccini M, Iannone A, Maselli R, Jovani M, Chandrasekar VT, et
  417 al. Performance of artificial intelligence in colonoscopy for adenoma and polyp
  418 detection: a systematic review and meta-analysis. Gastrointest Endosc.
  419 2021;93:77-85.e6.
- 420 26. van Leeuwen KG, Schalekamp S, Rutten MJCM, van Ginneken B, de Rooij M.
  421 Artificial intelligence in radiology: 100 commercially available products and
  422 their scientific evidence. Eur Radiol. 2021;31:3797-804.
- 423 27. Checcucci E, De Cillis S, Amparore D, Gabriele V, Piramide F, Piana A, et al.
  424 Artificial Intelligence alert systems during robotic surgery: a new potential tool
  425 to improve the safety of the intervention. Urol Vid J. 2023;18:100221.
- Halabi WJ, Jafari MD, Nguyen VQ, Carmichael JC, Mills S, Pigazzi A, et al.
  Ureteral injuries in colorectal surgery: an analysis of trends, outcomes, and risk
  factors over a 10-year period in the United States. Dis Colon Rectum.
  2014;57:179-86.
- Palaniappa NC, Telem DA, Ranasinghe NE, Divino CM. Incidence of iatrogenic
  ureteral injury after laparoscopic colectomy. Arch Surg. 2012;147:267-71.

432	30.	Marcelissen TA, Den Hollander PP, Tuytten TR, Sosef MN. Incidence of
433		iatrogenic ureteral injury during open and laparoscopic colorectal surgery: A
434		single center experience and review of the literature. Surg Laparosc Endosc
435		Percutan Tech. 2016;26:513-5.

- 436 31. Giglia MD, Stein SL. Overlooked long-term complications of colorectal surgery. 437
- Clin Colon Rectal Surg. 2019;32:204-11.
- Adam JP, Denost Q, Capdepont M, et al. Prospective and longitudinal study of 438 32.
- urogenital dysfunction after proctectomy for rectal cancer. Dis Colon Rectum. 439
- 2016;59:822-30. 440
- 441

#### 442 **Figure legends**

- Figure 1: Trial flow diagram 443
- Figure 2: Example of the monitor layout in an operation room 444
- The system output (semantic segmentation pixels) is superimposed on a sub-monitor 445
- 446 placed adjacent to the main monitor, and does not affect the main monitor.

447

#### **Additional files** 448

- Additional file 1: Ethical approval document (English translation version) 449
- Additional file 2: Copy of the original funding documentation (English translation 450
- version) 451
- Additional file 3: A completed SPIRIT checklist 452
- 453 Additional file 4: A SPIRIT figure

## SPIRIT-AI Checklist: Recommended items to address in a protocol and related documents for clinical trials evaluating AI interventions

4 5

Section		SPIRIT 2013 Item <sup>a</sup>	SPIRIT-AI Item			Addressed on Page No <sup>b</sup>
		Administrative II	nformation			
		Descriptive title identifying the study design, population, interventions, and, if	SPIRIT-AI Elaboration	1(i)	Indicate that the intervention involves artificial intelligence / machine learning and specify the type of model.	1
Title	1	applicable, trial acronym	SPIRIT-AI Elaboration	1(ii)	Specify the intended use of the AI intervention.	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry				4
	2b	All items from the World Health Organization Trial Registration Data Set				4
Protocol version	3	Date and version identifier				N/A
Funding	4	Sources and types of financial, material, and other support				17
	5a	Names, affiliations, and roles of protocol contributors				1
	5b	Name and contact information for the trial sponsor				1-2
Roles and responsibilities	5с	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities				17
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)				17
	Introduction					

				Explain the intended use of the AI intervention in the	6-7
		Description of research question and justification for undertaking the trial,	SPIRIT-AI 6a (i)	context of the clinical pathway, including its purpose and its	
			Extension	intended users (e.g. healthcare professionals, patients,	
Background and	6a	including summary of relevant studies (published and unpublished)		public).	
rationale		examining benefits and harms for each intervention	SPIRIT-AL 62 (ii)		6-7
			Extension	Describe any pre-existing evidence for the AI intervention.	0-7
	65	Evaluation for choice of comparators			6-7
	00				0-7
Objectives	7	Specific objectives or hypotheses			7
		Description of trial design including type of trial (eg, parallel group,			7-8
Trial design	8	crossover, factorial, single group), allocation ratio, and framework (eg,			
		superiority, equivalence, noninferiority, exploratory)			
		Methods: Participants, Interv	entions and Outcome	es	
		Description of study settings (eg, community clinic, academic hospital)			8
Study setting	9	and list of countries where data will be collected. Reference to where list	SPIRIT-AI 9	Describe the onsite and offsite requirements needed to	
		of study sites can be obtained	Extension	integrate the AI intervention into the trial setting.	
			SPIRIT-AI 10 (i)	State the inclusion and exclusion criteria at the level of	9
		Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Elaboration	participants.	
Eligibility criteria	10		SPIRIT-AI 10 (ii)	State the inclusion and exclusion criteria at the level of the	9
			Extension	input data.	
			SPIRIT-AI 11a (i)		9-10
			Extension	State which version of the AI algorithm will be used.	
			SPIRIT-AI 11a (ii)	Specify the procedure for acquiring and selecting the input	9-10
	11a	Interventions for each group with sufficient detail to allow replication,	Extension	data for the AI intervention.	
Interventions		including how and when they will be administered	SPIRIT-AI 11a	Specify the procedure for assessing and handling poor	9-10
			(iii) Extension	quality or unavailable input data.	
		SPIRIT-AI 11a	Specify whether there is human-AI interaction in the	9-10	

			(iv) Extension	handling of the input data, and what level of expertise is	
				required for users.	
			SPIRIT-AI 11a (v) Extension	Specify the output of the AI intervention.	9-10
				Explain the procedure for how the AI intervention's output	9-10
				will contribute to decision-making or other elements of	
				clinical practice.	
		Criteria for discontinuing or modifying allocated interventions for a given			9-10
	11b	trial participant (eg, drug dose change in response to harms, participant			
		request, or improving/worsening disease)			
		Strategies to improve adherence to intervention protocols, and any			9-10
	11c	procedures for monitoring adherence (eg, drug tablet return, laboratory			
		tests)			
	44.1	Relevant concomitant care and interventions that are permitted or			9-10
	110	prohibited during the trial			
		Primary, secondary, and other outcomes, including the specific			10
	12	measurement variable (eg, systolic blood pressure), analysis metric (eg,			
0.4		change from baseline, final value, time to event), method of aggregation			
Outcomes		(eg, median, proportion), and time point for each outcome. Explanation of			
		the clinical relevance of chosen efficacy and harm outcomes is strongly			
		recommended			
Destisie ent		Time schedule of enrolment, interventions (including any run-ins and			10-11
Participant	13	washouts), assessments, and visits for participants. A schematic diagram			
timeline		is highly recommended (see Figure)			
		Estimated number of participants needed to achieve study objectives and			11-12
Sample size	14	how it was determined, including clinical and statistical assumptions			

		supporting any sample size calculations				
		Strategies for achieving adequate participant enrolment to reach target			8	
Recruitment	15	sample size				
		Methods: Assignment of Interven	tions (For Controlled	Trials)		
		Method of generating the allocation sequence (eg, computer-generated			12	
		random numbers), and list of any factors for stratification. To reduce				
Sequence	16A	predictability of a random sequence, details of any planned restriction				
generation		(eg, blocking) should be provided in a separate document that is				
		unavailable to those who enrol participants or assign interventions				
A.II		Mechanism of implementing the allocation sequence (eg, central	-		12	
Allocation		telephone; sequentially numbered, opaque, sealed envelopes),				
concealment	16b	describing any steps to conceal the sequence until interventions are				
mechanism		assigned				
	4.0	Who will generate the allocation sequence, who will enrol participants,			12	
Implementation	160	and who will assign participants to interventions				
	47-	Who will be blinded after assignment to interventions (eg, trial			12	
	1 <i>1</i> a	participants, care providers, outcome assessors, data analysts), and how				
Blinding (masking)		If blinded, circumstances under which unblinding is permissible, and			12	
	17b	procedure for revealing a participant's allocated intervention during the				
		trial				
	Methods: Data Collection, Management, And Analysis					
		Plans for assessment and collection of outcome, baseline, and other trial			12-13	
Data collection		data, including any related processes to promote data quality (eg,				
mothods	18a	duplicate measurements, training of assessors) and a description of				
menious		study instruments (eg, questionnaires, laboratory tests) along with their				
		reliability and validity, if known. Reference to where data collection forms				

23

	_			
		can be found, if not in the protocol		
		Plans to promote participant retention and complete follow-up, including		12-13
	18b	list of any outcome data to be collected for participants who discontinue		
		or deviate from intervention protocols		
		Plans for data entry, coding, security, and storage, including any related		12-13
		processes to promote data quality (eg, double data entry; range checks		
Data management	19	for data values). Reference to where details of data management		
		procedures can be found, if not in the protocol		
		Statistical methods for analysing primary and secondary outcomes.		13
	20a	Reference to where other details of the statistical analysis plan can be		
		found, if not in the protocol		
		Methods for any additional analyses (eg, subgroup and adjusted		13
Statistical methods	20b	analyses)		
		Definition of analysis population relating to protocol non-adherence (eg,		13
	20c	as randomised analysis), and any statistical methods to handle missing		
		data (eg, multiple imputation)		
		Methods: Mo	nitoring	
		Composition of data monitoring committee (DMC); summary of its role		13-14
		and reporting structure; statement of whether it is independent from the		
	21a	sponsor and competing interests; and reference to where further details		
Data monitoring		about its charter can be found, if not in the protocol. Alternatively, an		
		explanation of why a DMC is not needed		
		Description of any interim analyses and stopping guidelines, including		13-14
	21b	who will have access to these interim results and make the final decision		

		to terminate the trial			
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	SPIRIT-AI 22 Extension	2 Specify any plans to identify and analyse performance errors. If there are no plans for this, explain why not.	13-14
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor			13-14
		Ethics and Diss	emination		
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval			14-15
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)			14-15
Consent or ascent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)			14-15
	26b	and biological specimens in ancillary studies, if applicable			14-13
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial			14-15
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site			14-15
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	SPIRIT-AI 25 Extension	State whether and how the AI intervention and/or its code can be accessed, including any restrictions to access or re-use.	14-15
Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and for compensation			14-15

post-trial care		to those who suffer harm from trial participation	
Dissemination	31a	Plans for investigators and sponsor to communicate trial results to         participants, healthcare professionals, the public, and other relevant         groups (eg, via publication, reporting in results databases, or other data         sharing arrangements), including any publication restrictions         Authorship eligibility guidelines and any intended use of professional	14-15
policy	31b	writers	14-15
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	14-15
	·	Appendices	
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	N/A
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological         specimens for genetic or molecular analysis in the current trial and for         future use in ancillary studies, if applicable	N/A

<sup>6</sup> <sup>a</sup> It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.

<sup>b</sup> Indicates page numbers to be completed by authors during protocol development

27

	STUDY PERIOD				
	Enrolment	Allocation	Post-allocation		Close-out
TIMEPOINT	-t <sub>1</sub>	0	OP*	Post-OP	POM1**
ENROLMENT:					
Eligibility screen	Х				
Informed consent	Х				
Allocation		Х			
INTERVENTIONS:					
Without AI navigation			х		
With AI navigation			Х		
ASSESSMENTS:					
Baseline variables	Х	Х			
Postoperative variables				х	х
Follow-up variables					х

# SPIRIT figure: The schedule of enrolment, interventions, and assessments.

\*OP: date of operation \*\*POM1: postoperative month 1



